- Home
- UNCY vs CNTX Comparison
UNCY vs CNTX Comparison
Compare UNCY & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | CNTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 47.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UNCY | CNTX |
|---|---|---|
| Price | $4.47 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $25.67 | $6.60 |
| AVG Volume (30 Days) | 724.6K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $582.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $0.32 |
| 52 Week High | $8.74 | $3.62 |
Technical Indicators
Market Signals| Indicator | UNCY | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.88 | 29.42 |
| Support Level | $3.93 | N/A |
| Resistance Level | $5.78 | $0.40 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 11.57 | 5.24 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.